Immunotherapy for hepatocellular carcinoma:molecular pathogenesis and clinical research progress

作     者：Xue-Song Li Feng Xia Xue-Song Li;Feng Xia

作者机构：Institute of Hepatobiliary Surgery and Southwest Cancer CenterSouthwest HospitalArmy Medical UniversityChongqingChina 

出 版 物：《Oncology and Translational Medicine》 (肿瘤学与转化医学（英文版）)

年 卷 期：2023年第9卷第5期

页      面：206-212页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by a grant from the National Natural Sciences Foundation of China(No.81773140). 

主　　题：Immunotherapy Hepatocellular carcinoma Immune checkpoint inhibitor Cancer vaccine 

摘      要：The treatment of hepatocellular carcinoma(HCC)is advancing rapidly in the 21st century.Although there are various treatment methods,the most promising breakthrough seems to be in immunotherapy.Recent guidelines from the American Society of Clinical Oncology and the European Association for the Study of the Liver have recommended immunotherapieswith strong antitumor effects for HCC treatment.Emerging systemic therapeutic strategies,such as immune checkpoint inhibitors combined with targeted therapy or local treatment,are among the most promising for improving overall and tumor-free survival times in patients with HCC.This review analyzes the molecular mechanisms of existing immune checkpoint inhibitors,vaccines,and chimeric antigen receptor–T cells;summarizes the latest progress in relevant clinical research;and outlines future trends and opportunities for HCC immunotherapy.